Trial reportBlood advances2018
Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial).
Trial report in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02973360 (A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Antioxidant supplementation for sickle cell disease.The Cochrane database of systematic reviews · 2024Pooled it
- Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease.Pharmacotherapy · 2022Trial
- Enhanced PIEZO1 function contributes to the pathogenesis of sickle cell disease.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Using disease-modifying therapies in sickle cell disease.Hematology. American Society of Hematology. Education Program · 2023Article
- Review
- Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative.Frontiers in genetics · 2022Article
- Pain in sickle cell disease: current and potential translational therapies.Translational research : the journal of laboratory and clinical medicine · 2021Review
- SC411 treatment can enhance survival in a mouse model of sickle cell disease.Prostaglandins, leukotrienes, and essential fatty acids · 2020Article
- Integrative approaches to treating pain in sickle cell disease: Pre-clinical and clinical evidence.Complementary therapies in medicine · 2020Review
- Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.Therapeutic advances in hematology · 2020Review
- Drug Therapies for the Management of Sickle Cell Disease.F1000Research · 2020Review
- Relationship of Omega-3 fatty acids DHA and EPA with the inflammatory biomarker hs-CRP in children with sickle cell anemia.Prostaglandins, leukotrienes, and essential fatty acids · 2019Article
- Redox Signaling in Sickle Cell Disease.Current opinion in physiology · 2019Article
- Dietary fatty acids fine-tune Piezo1 mechanical response.Nature communications · 2019Article
- Advanced Lipid Technologies® (ALT®): A Proven Formulation Platform to Enhance the Bioavailability of Lipophilic Compounds.Journal of drug delivery · 2019Review
- New Therapeutic Options for the Treatment of Sickle Cell Disease.Mediterranean journal of hematology and infectious diseases · 2019Review
- New insights into the pathophysiology and development of novel therapies for sickle cell disease.Hematology. American Society of Hematology. Education Program · 2018Review
- Omega 3 fatty acids - Potential modulators for oxidative stress and inflammation in the management of sickle cell disease.Jornal de pediatriaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 1 country.
Funding
Abstract
Blood cell membranes in sickle cell disease (SCD) have low docosahexaenoic acid (DHA). DHA treatment reduces sickle cell crisis (SCC) rate and ameliorates the inflammation, oxidative stress, and hypercoagulable state of SCD. SC411 is a novel DHA ethyl ester formulation with a proprietary delivery platform (Advanced Lipid Technology) that enhances DHA bioavailability. The SCOT trial investigated the effect of 3 different doses of SC411 on clinical and biochemical endpoints in 67 children with SCD (5-17 years old). Seventy-six percent of subjects were also receiving hydroxyurea. After 4 weeks of treatment with SC411 at 20, 36, and 60 mg DHA/kg per day or placebo a statistically significant (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.